Ethics&Compliance Manager Poland&Baltics, CZ, SK& HU

PMI Vision It’s Time to Unsmoke. There is no question that the best choice for men and women who smoke is to quit cigarettes and nicotine altogether. But many people don’t. In any given year, about 9 out of 10 men and women who are already smoking will continue: those people deserve access to, and information about, better alternatives. That is why we’re building PMI’s future on smoke-free products and focusing our efforts in switching adults, who choose to continue smoking, to our smoke-free products. In order to achieve this, we are focused on 6 strategic priorities: • Developing a long-term product and ecosystem portfolio, • Building societal support of smoke-free products, • Growing our smoke-free product categories to scale, • Delivering product launch & customer service agility, • Achieving cost and cash leadership, and • Maintaining leadership in conventional cigarettes. About Our Vision We’ve built the world’s most successful cigarette company, with the world’s most popular and iconic brands. Now we’ve made a dramatic decision. We will be far more than a leading cigarette company. We’re building PMI’s future on smoke-free products that are a much better choice than cigarette smoking. Indeed, our vision – for all of us at PMI – is that these products will one day replace cigarettes. Why are we doing this? Because we should … We understand the millions of men and women who smoke cigarettes. They are looking for less harmful, yet satisfying, alternatives to smoking. We will give them that choice. We have a commitment to our employees and our shareholders. We will fulfill that commitment by pursuing this long-term vision for success. Society expects us to act responsibly. And we are doing just that, by delivering a smoke-free future. … And because we now can. Success in the cigarette business gives us the resources to pursue our ambitious vision. Thanks to the imagination and perseverance of thousands of people at PMI, we have developed breakthrough products that are smoke-free and enjoyable. About IQOS The U.S. Food and Drug Administration (FDA) has authorized the marketing of our flagship electronically heated tobacco system, IQOS, as a modified risk tobacco product (MRTP), which represents a historic opportunity for public health. In doing so, the agency found that issuing an exposure modification order for the IQOS Tobacco Heating System (THS) is appropriate to promote the public health, and is expected to benefit the health of the population as a whole. This decision demonstrates that IQOS is fundamentally different from combustible cigarettes, and a better choice for adults who would otherwise continue smoking. It follows a review of the extensive scientific evidence package PMI submitted to the FDA in December 2016 to support its MRTP applications. The FDA’s action authorizes the marketing of IQOS in the USA with the following information: * The IQOS system heats tobacco but does not burn it. * This significantly reduces the production of harmful and potentially harmful chemicals. * Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals. In April 2019, the agency authorized IQOS for sale in the U.S. through issuance of premarket tobacco product application marketing orders, that deemed marketing the product to be appropriate for the protection of the public health. Now, the FDA has concluded issuing an IQOS exposure modification order is appropriate to promote the public health, and is expected to benefit the health of the population as a whole, taking into account both users and nonusers of tobacco products. Notably, the FDA’s issuance of an exposure modification MRTP order does not mean IQOS is FDA-approved. FDA does not ‘approve’ tobacco products. Further, the FDA’s decision does not mean IQOS is risk-free. The FDA’s decision is consistent with earlier conclusions of other leading regulatory and scientific bodies, including in the U.K., Germany, and the Netherlands, which have found that the product emits lower levels of harmful toxicants. Furthermore, the FDA’s MRTP authorization shows that IQOS is a fundamentally different product than combustible cigarettes, and must be regulated differently, as the FDA has recognized. As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to IQOS. We believe that this decision can help to further accelerate the transition of U.S. adults away from cigarettes. We, along with our licensee Altria, are committed to guarding against unintended use and fully support FDA’s focus on protecting youth. Role Summary Support the Local Compliance Officer with developing and overseeing the compliance program in Poland (including the PMI Service Center Europe), Estonia, Latvia, Lithuania, the Czech Republic, Slovakia and Lithuania. Support the Local Compliance Officer in driving the mission of Global PMI Compliance to: • Empower and enable management, employees and close third parties to meet applicable external (legal, regulatory, industry) and internal (policy) requirements by providing them with the tools, knowledge and advice to do their jobs in an ethical and compliant way • Assess risk, monitor ongoing compliance, test compliance controls, and investigate allegations of potential non-compliance • Drive a culture of compliance that encourages raising concerns about potential or actual compliance violations and pro-active addressing of issues Key Responsibilities Support the Local Compliance Officer with driving and delivering compliance initiatives in all five pillars of the PMI Global Compliance Program, with a focus on Code of Conduct, Conflicts of Interests, Whistleblowing and Investigations, as well as legal compliance topics such as Anti-Bribery, Competition law, etc. 1. Governance • Identify, assess, and manage compliance risks • Stay current with ethics and compliance developments, best practices and benchmarks 2. Policy & Processes • Support with the develop and implement compliance policies and processes • Oversee and execute compliance processes 3. Training & Communications • Raise and maintain awareness about compliance • Provide face-to-face training to different types and of audiences • Oversee and support e-learning 4. Monitoring & Investigations • Support or conduct internal investigations • Enhance and maintain culture of speaking up • Monitor the effectiveness of compliance program 5. Advisory • Support employees seeking compliance advice in the market • Support with providing compliance input and advice on strategic business matters • Identify and analyze compliance issues and present recommendations. Profile • At least 2 years of experience as a compliance officer or in-house counsel • University Degree in Law, Business or other relevant field • Fluent in written and spoken English, as well as Polish • Knowledge and applied understanding of compliance programs and subject matters • Experience working in a heavily regulated industry with many touchpoints with government authorities, such as pharma, medtech, extractive industries, defense industry, etc., a plus • Experience in supporting complex investigations and inquiries Skills 1. Integrity 2. Level-headed 3. Issue spotting and critical thinking 4. Ability to manage and oversee complex processes 5. Written and verbal communications skills PMI is an Equal Opportunity Employer PMI Global Services Inc. and PM Global Brands Inc. are a subsidiary of Philip Morris International Inc. Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2022, PMI's smoke-free products are available for sale in 70 markets in key cities or nationwide, and PMI estimates that approximately 13.5 million adults around the world, excluding Russia and Ukraine have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com. #LI-Hybrid